mCELL™ is a viable bone marrow–derived MSC product sourced from young adult donor material and designed for localized physician-directed use. It combines a clinically relevant MSC source with controlled manufacturing, lot-level documentation, and practical vial-based delivery.
– 01 –
A clinically familiar adult MSC source with orthopedic relevance.
Bone marrow biology has long been used in orthopedics through approaches such as BMAC, marrow stimulation, and microfracture.
mCELL™ builds on that foundation with viable adult BM-MSCs manufactured for off-the-shelf physician use.
– 01 –
A clinically familiar adult MSC source with orthopedic relevance.
– 01 –
A clinically familiar adult MSC source with orthopedic relevance.
Every vial is supported by traceable manufacturing and release documentation.
BM-MSCs like mCELL™ are responsive to their local environment, secreting a bespoke set of healing factors. These factors promote new blood vessel growth (VEGF), help regrow needed connective tissue (TIMP-2) and reduce inflammation (IDO).
Together, these factors inhibit further degeneration, enable healing, and drive regeneration.
In standardized laboratory testing, BM-MSCs demonstrated greater ability to address inflammation and greater blood vessel formation and tissue repair compared to UC-MSCs under identical conditions.
Corticosteroids and hyaluronic acid may support symptom management or joint lubrication. They do not contain the regenerative properties of viable MSCs.
PRP and BMAC are patient-derived and widely used. Composition can vary based on the patient, collection method, and processing approach.
Physicians have multiple injection-based options, but they differ in source, mechanism, variability, processing, documentation, and whether they contain viable living cells.
mCELL™ is a viable, bone marrow–derived MSC product designed for off-the-shelf physician use, with lot-level testing, documentation, post-thaw viability support, and traceability.
Exosomes and secretome products are cell-derived. They do not contain viable living cells and are not compliant with FL’s SB 1768.
Products derived from birth tissue sources such as umbilical cord, Wharton’s jelly, or related perinatal tissues. These products vary by source and developmental context and viability and cellular content can vary by product.
